Salud financiera de hoja de balance de Rhythm Biosciences

Salud financiera controles de criterios 6/6

Rhythm Biosciences tiene un patrimonio de los accionistas total de A$1.2M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$1.9M y A$701.1K respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$1.26m
Patrimonio	AU$1.24m
Total pasivo	AU$701.07k
Activos totales	AU$1.94m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Recent updates

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

Dec 06

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Aug 09

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Apr 11

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$1.4M) de RHY superan a sus pasivos a corto plazo (A$679.4K).

Pasivo a largo plazo: Los activos a corto plazo de RHY (A$1.4M) superan a sus pasivos a largo plazo (A$21.7K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: RHY está libre de deudas.

Reducción de la deuda: RHY no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 1.1%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RHY tiene suficiente cash runway para 2 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que RHY disponga de suficiente cash runway para 2 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Rhythm Biosciences

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Recent updates

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

New major risk - Share price stability

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New minor risk - Shareholder dilution

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

New minor risk - Financial data availability

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Executive Chairman recently bought AU$248k worth of stock

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Less than half of directors are independent

Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022

Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer

Executive Chairman recently sold AU$6.5m worth of stock

Executive Chairman exercised options to buy AU$459k worth of stock.

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers

Less than half of directors are independent

Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ®

Rhythm Biosciences Ltd Announces Executive Changes

Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Non-Executive Director David White has left the company

Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial

Rhythm Biosciences Betters ColoSTAT Results

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

New 90-day high: AU$1.64

Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site

New 90-day high: AU$1.56

Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites

New 90-day high: AU$1.38

New 90-day high: AU$0.88

Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

New 90-day high: AU$0.28

New 90-day high: AU$0.21

Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial

New 90-day high - AU$0.20

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million.

Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera